SECTOR:
Oncology
FUND/VEHICLE:
Pivotal US
INVESTMENT DATE:
2019
GEOGRAPHY:
North America
STATUS CURRENT/FORMER INVESTMENT:
Existing
WEBSITE:
A clinical stage biopharmaceutical company with the goal of curing cancer by developing targeted alpha therapeutics. They see targeted alpha therapeutics as the next generation of radiation therapy. At Fusion, they are pushing the boundaries of science to create innovative cancer treatments. They believe that targeted alpha therapeutics represent the evolution of radiopharmaceuticals which holds great promise to improve the lives of patients with cancer.